Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
KalVista Pharmaceuticals, Inc. KALV
$9.70
-$0.03 (-0.31%)
На 18:00, 12 мая 2023
+291.75%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
331101486.00000000
-
week52high
17.06
-
week52low
4.12
-
Revenue
0
-
P/E TTM
-4
-
Beta
1.09515500
-
EPS
-3.68000000
-
Last Dividend
0.00000000
-
Next Earnings Date
05 июл 2023 г. в 12:30
Описание компании
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, a plasma kallikrein inhibitor that completed a Phase II clinical trial for the treatment of DME; sebetralstat, which is initiation of the Phase 3 KONFIDENT trial as a potential oral, on-demand therapy for HAE attacks; KVD824, an oral product candidate for the treatment of HAE; and Factor XIIa, an oral inhibitor program which is in preclinical stage targets an enzyme in HAE. The company is headquartered in Cambridge, Massachusetts.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| SVB Leerink | Outperform | Outperform | 08 июл 2022 г. |
| Needham | Buy | Buy | 08 июл 2022 г. |
| Stifel | Buy | Buy | 08 июн 2022 г. |
| Needham | Buy | Buy | 11 мар 2022 г. |
| Needham | Buy | Buy | 10 дек 2021 г. |
| HC Wainwright & Co. | Buy | Buy | 06 окт 2022 г. |
| SVB Leerink | Outperform | Outperform | 05 окт 2022 г. |
| Needham | Buy | Buy | 04 окт 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Yea Christopher | D | 34232 | 1139 | 18 ноя 2022 г. |
| Feener Edward P. | D | 62376 | 530 | 18 ноя 2022 г. |
| Palleiko Benjamin L | D | 68390 | 722 | 18 ноя 2022 г. |
| Audhya Paul K. | D | 5946 | 722 | 18 ноя 2022 г. |
| Crockett Thomas Andrew | D | 114878 | 1785 | 18 ноя 2022 г. |
| Yea Christopher | D | 24833 | 1774 | 17 ноя 2022 г. |
| Yea Christopher | A | 35371 | 1774 | 17 ноя 2022 г. |
| Feener Edward P. | D | 24833 | 1774 | 17 ноя 2022 г. |
| Feener Edward P. | A | 62906 | 1774 | 17 ноя 2022 г. |
| Palleiko Benjamin L | D | 33863 | 2419 | 17 ноя 2022 г. |
Новостная лента
KalVista Pharmaceuticals to Present Data at the 13th C1-inhibitor Deficiency & Angioedema Workshop
Business Wire
27 апр 2023 г. в 06:30
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced the acceptance of multiple abstracts at the 13th C1-inhibitor Deficiency & Angioedema Workshop taking place in Budapest, Hungary from May 4-7. The presentations are: Route of Administration Preferences of People with Hereditary An.
Here's Why You Can Add KalVista (KALV) Stock to Your Portfolio
Zacks Investment Research
12 апр 2023 г. в 12:09
Here we discuss some reasons why investing in KalVista Pharmaceuticals (KALV) stock now is a good idea.
KalVista Pharmaceuticals to Present at 22nd Annual Needham Virtual Healthcare Conference
Business Wire
12 апр 2023 г. в 06:30
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced it will participate in a fireside chat at the 22nd Annual Needham Virtual Healthcare Conference on Thursday, April 20, 2023 at 11:00 a.m. ET. A live webcast of the presentation will be available on the Company's website at www.
Wall Street Analysts Think KalVista Pharmaceuticals, Inc. (KALV) Could Surge 145.98%: Read This Before Placing a Bet
Zacks Investment Research
04 апр 2023 г. в 11:24
The consensus price target hints at a 146% upside potential for KalVista Pharmaceuticals, Inc. (KALV). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
KalVista Pharmaceuticals, Inc. (KALV) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
Zacks Investment Research
22 мар 2023 г. в 11:29
KalVista Pharmaceuticals, Inc. (KALV) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.